Spinraza
Roche builds evidence for Evrysdi’s benefits in younger SMA patients
Phil Taylor
Biogen, Evrysdi, Novartis, Roche, spinal muscular atrophy, Spinraza, Zolgensma
0 Comment
Biogen plans trial of Spinraza in patients not responding to SMA gene therapy
Richard Staines
Biogen, gene therapy, Novartis, Rare diseases, SMA, Spinraza, Zolgensma
0 Comment
FDA cues up May verdict for Roche’s SMA challenger risdiplam
Phil Taylor
Biogen, Novartis, Risdiplam, Roche, spinal muscular atrophy, Spinraza, Zolgensma
0 Comment
NHS chief hails SMA drug deal – and was that a swipe at Vertex?
Richard Staines
Biogen, market access, NICE, Rare diseases, Spinraza
0 Comment
PTC shares soar after SMA drug data impresses market
Piotr Wnuk
AveXis, Biogen, Novartis, PTC Therapeutics, SMA, spinal muscular atrophy, Spinraza
0 Comment
Market Access/ News/ News/ Pharma Market Access
Biogen sees Spinraza slow down in Q3, bullish on Alzheimer’s chances
Andrew McConaghie
Alzheimer's disease, Biogen, Spinraza
0 Comment